Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study.
In order to update the epidemiological and mycological profile of candidaemia in Europe, the European Confederation of Medical Mycology conducted a prospective, sequential, hospital population-based study from September 1997 to December 1999. A total of 2,089 cases were documented by 106 institutions in seven European countries. Rates of candidaemia ranging from 0.20 to 0.38 per 1,000 admissions were reported. Candida albicans was identified in 56% of cases. Non-albicans Candida species were most frequently isolated from patients with haematological malignancies (65%). With increasing age, an increasing incidence of Candida glabrata was seen. The 30-day mortality rate was 37.9%. The survey results underline the burden of candidaemia in a wide range of patient populations, confirm the importance of non- albicans species, and provide baseline data for future surveillance studies at a European level.
Tortorano
A M
AM
Istituto di Igiene e Medicina Preventiva, Università degli Studi, IRCCS Ospedale Maggiore, Via F. Sforza 35, 20122 Milan, Italy. annamaria.tortorano@unimi.it
Peman
J
J
Bernhardt
H
H
Klingspor
L
L
Kibbler
C C
CC
Faure
O
O
Biraghi
E
E
Canton
E
E
Zimmermann
K
K
Seaton
S
S
Grillot
R
R
D000328:Adult; D017677:Age Distribution; D000368:Aged; D000935:Antifungal Agents / Q000627:therapeutic use; D002175:Candida / Q000145:classification* / Q000187:drug effects; D002177:Candidiasis / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*; D005060:Europe / Q000453:epidemiology; D005260:Female; D016469:Fungemia / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*; D006306:Health Surveys; D006801:Humans; D015994:Incidence; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D012307:Risk Factors; D017678:Sex Distribution; D015996:Survival Rate
D000935:Antifungal Agents